Circulation:血清PCSK9浓度或可作为心血管事件的预测因素

2016-03-27 Seven L 译 MedSci原创

近期发表在Circulation的研究称,血清PCSK9浓度可作为CVD事件的预测因子,就算是校正了传统的CVD风险因素(包括LDL胆固醇),两者间的联系仍存在。瑞典卡罗林斯卡学院环境医学研究所的Karin Leander博士和同事在1997年8月-1998年12月间纳入4232名参与者(男性2039名,女性2193名)进行了一项前瞻性队列研究,探究血清PCSK9浓度和CVD发生率之间的关系。所有

近期发表在Circulation的研究称,血清PCSK9浓度可作为CVD事件的预测因子,就算是校正了传统的CVD风险因素(包括LDL胆固醇),两者间的联系仍存在。

瑞典卡罗林斯卡学院环境医学研究所的Karin Leander博士和同事在1997年8月-1998年12月间纳入4232名参与者(男性2039名,女性2193名)进行了一项前瞻性队列研究,探究血清PCSK9浓度和CVD发生率之间的关系。所有参与者在纳入研究时居住在瑞典斯德哥尔摩郡,年龄60岁,通过ELISA检测血清PCSK9浓度和其他基线资料。随访到2012年12月31日,通过国家登记库识别CVD事件。研究以CVD事件的发生率、卒中和死亡作为主要结局指标,其中CVD事件包括MI、不稳定心绞痛、突发心脏骤停和CHD。研究中校正的因素有糖尿病、BMI、运动、吸烟、高血压和高胆固醇血症。

研究数据显示,随访的490438人-年里发生了485例CVD事件(男性304名,女性181名)。总体而言的中位数血清PCSK9浓度为94.3 ng/mL,不过女性的平均值高于男性(108.9 ng/mL vs. 80.5 ng/mL)。将所有参与者按照血清PCSK9浓度由低到高分为四组,三组和四组的人群主要是女性、糖尿病或前驱糖尿病、超重、吸烟和不运动的人群。他汀类药物的使用较少,不过三组和四组的人群更可能使用他汀类药物。

血清PCSK9浓度和CVD事件之间的关联系数为0.18 (P < .0001),甘油三脂和血清PCSK9浓度的关联系数为0.12 (P < .001)。

校正CVD相关的其他危险因素(包括升高的LDL)后,Leander和同事发现血清PCSK9浓度和CVD事件显著相关(HR = 1.15; 95% CI, 1.05-1.26)。此外,随着血清PCSK9浓度由低到高,CVD风险逐渐增加,四组的人群中,CVD事件的HR=1.48 (95% CI, 1.12-1.95; P = .0063)。

研究结果表明,血清PCSK9浓度或许可以作为CVD事件的预测因素,不过未来还需要更多的研究验证该结果,如果两者间关系成立,那么个体将会受益于PCSK9抑制剂的治疗,或者PCSK9本身就可以作为治疗的靶目标。

原始出处:


Leander K, et al. Circulating PCSK9 Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.Circulation. 2016;doi:10.1161/CIRCULATIONAHA.115.018531.

Circulating PCSK9 predicts risk for CVD events.Healio.March 27, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643401, encodeId=d5581643401a9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Oct 21 14:10:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777238, encodeId=da461e7723857, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 24 01:10:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685578, encodeId=895516855e8b8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Thu Sep 08 08:10:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264222, encodeId=cefd1264222c9, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544412, encodeId=5216154441204, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643401, encodeId=d5581643401a9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Oct 21 14:10:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777238, encodeId=da461e7723857, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 24 01:10:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685578, encodeId=895516855e8b8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Thu Sep 08 08:10:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264222, encodeId=cefd1264222c9, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544412, encodeId=5216154441204, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=)]
    2016-06-24 FukaiBao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643401, encodeId=d5581643401a9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Oct 21 14:10:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777238, encodeId=da461e7723857, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 24 01:10:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685578, encodeId=895516855e8b8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Thu Sep 08 08:10:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264222, encodeId=cefd1264222c9, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544412, encodeId=5216154441204, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=)]
    2016-09-08 Tamikia
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643401, encodeId=d5581643401a9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Oct 21 14:10:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777238, encodeId=da461e7723857, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 24 01:10:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685578, encodeId=895516855e8b8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Thu Sep 08 08:10:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264222, encodeId=cefd1264222c9, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544412, encodeId=5216154441204, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643401, encodeId=d5581643401a9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Oct 21 14:10:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777238, encodeId=da461e7723857, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 24 01:10:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685578, encodeId=895516855e8b8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Thu Sep 08 08:10:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264222, encodeId=cefd1264222c9, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544412, encodeId=5216154441204, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Mar 29 14:10:00 CST 2016, time=2016-03-29, status=1, ipAttribution=)]

相关资讯

Vaccine:降低低密度脂蛋白(LDL)的疫苗已在动物上初显成效

研究人员表明,与他汀类药物相比,预防高胆固醇疫苗可能是更有效。该疫苗为PCSK9抑制剂,PCSK9是一种调节血液中胆固醇的数量的蛋白。2015年FDA批准Alirocumab和Evolocumab上市。这两种新型降脂药虽然效果优于他汀类,但是价格非常昂贵!虽然现在他汀类得到广泛使用,但是并不能对每一个人都有效。新墨西哥大学和美国国立卫生研究院的研究者在《Vaccine》上发表文章称,他们发明了一种

NEJM:PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件(OSLER研究)

Evolocumab是一种单克隆抗体,为PCSK9抑制剂,先前短期研究发现,Evolocumab可明显降低低密度脂蛋白胆固醇(LDL-C)水平。为了探究Evolocumab的长期有效性和安全性,研究者进行了两项非盲、随机的延伸试验,以获取数据分析该问题。

ETC-1002降低胆固醇比PCSK9有优势

美国生物制药公司Esperion最新研究表明ETC-1002不仅能降低坏胆固醇含量,还能改善炎症。 二期实验表明,与安慰剂相比,ETC-1002治疗高胆固醇、高血压效果显著。143名患者服用ETC-1002后坏胆固醇含量降低21%,与服用安慰剂组相比高了3%。 此外,与空白组相比,药物还可降低25%超敏C-反应蛋白(冠脉炎症标志物);与安慰剂相比, ETC-1002可以降低44%的超敏C-反

Lancet:PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究)

纯合子型家族性高胆固醇血症临床上极其罕见,是一种罕见的常染色体显性遗传性疾病,有家族性的特征,发生率仅为百万分之一。这类患者由于LDL受体缺乏,出生后不久,血清低密度脂蛋白(LDL)胆固醇水平很高。若为同合子患者时其低密度脂蛋白(LDL)胆固醇数值是正常人的4~6倍,通常LDL-C为500-1200mg/dL,甚至超过700mg/dL,但甘油三酯正常;也易于生命早期罹患心血管疾病。随年龄的增长,可

郭艺芳:PCSK9单克隆抗体能否撼动他汀霸主地位?

近期 ACC大会上先后公布的多项临床试验(LAPLACE-2, DESCARTES, MENDEL-2, RUTHERFORD-2, GAUSS-2等)初步论证了PCSK9抑制剂的降胆固醇作用,结果表明此类药物降低LDL-C的幅度可髙达50%以上。这一降幅相当于大中剂量的强效他汀。 与此同时,现有研究也显示此类药物具有良好的安全性与耐受性。至此,PCSK9抑制剂已经具备了作为优秀降胆固醇药物

JCEM:何种PCSK9基因突变类型能降低LDL-C水平?

研究背景: 血浆低密度脂蛋白胆固醇(LDL-C)水平的升高是动脉粥样硬化和心血管疾病的一个重要危险因素。血清前蛋白转化酶枯草溶菌素9(PCSK9)基因的突变不仅与血浆LDL-C水平有关,还与缺血性心脏病有关。然而,对于美国印第安人种中PCSK9的遗传结构特征及其对LDL-C水平的影响还知之甚少。 研究目的: 我们旨在研究美国印第安人种包含编码PCSK9基因染色体1p32区域的遗传